HighVista Strategies’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.96M Sell
205,954
-71,919
-26% -$2.83M 1.83% 9
2026
Q2
$10.7M Buy
277,873
+52,734
+23% +$1.61M 2.44% 5
2026
Q1
$5.59M Buy
225,139
+3,256
+1% +$84.3K 1.54% 11
2025
Q4
$5.64M Sell
221,883
-31,244
-12% -$697K 1.45% 19
2025
Q3
$4.08M Buy
253,127
+70,319
+38% +$1.14M 1% 25
2025
Q2
$2.92M Buy
182,808
+87,160
+91% +$1.32M 1.07% 18
2025
Q1
$1.63M Buy
+95,648
New +$2M 0.63% 57
2024
Q1
– Sell
-121,287
Closed -$5.11M – 141
2023
Q4
$5.11M Buy
121,287
+14,379
+13% +$529K 1.85% 4
2023
Q3
$4.1M Sell
106,908
-73,412
-41% -$1.66M 1.9% 5
2023
Q2
$3.42M Buy
180,320
+16,521
+10% +$308K 1.57% 14
2023
Q1
$2.54M Buy
+163,799
New +$2.84M 2.07% 14
2021
Q1
– Sell
-17,905
Closed -$827K – 134
2020
Q4
$827K Hold
17,905
– – 0.53% 41
2020
Q3
$630K Buy
+17,905
New +$539K 0.46% 26

Other funds holding IMVT

HighVista Strategies's IMVT Position: Q3 2026 in Review

HighVista Strategies reduced its Immunovant (IMVT) stake by 26% in Q3 2026, selling an estimated $2.83M and leaving 205,954 shares worth $6.96M. The position accounts for 1.83% of the portfolio, ranked #9.

HighVista Strategies first reported a position in IMVT in Q3 2020 and has held it in 13 quarters since. The position peaked at $10.7M in Q2 2026. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • HighVista Strategies held 205,954 shares of Immunovant worth $6.96M as of Q3 2026.
  • HighVista Strategies sold 71,919 Immunovant shares in Q3 2026, an estimated $2.83M.
  • Immunovant made up 1.83% of HighVista Strategies's portfolio in Q3 2026, its #9 holding.
  • HighVista Strategies first reported a position in Immunovant in Q3 2020 and has held it in 13 quarters since.
  • HighVista Strategies's Immunovant position peaked at $10.7M in Q2 2026.
  • 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on HighVista Strategies's 13F filing for Q3 2026, filed 13 Nov 2026.